Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis

By: via Benzinga
Novartis (NYSE: NVS) announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of people ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.